Pulmonx (LUNG) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUNG shares.
View LUNG analyst ratings or view top-rated stocks.

7 brokers have issued 1 year target prices for Pulmonx's stock. Their LUNG share price forecasts range from $8.00 to $20.00. On average, they predict the company's stock price to reach $14.75 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price.
View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts.

Pulmonx's stock was trading at $8.43 at the beginning of the year. Since then, LUNG stock has increased by 51.2% and is now trading at $12.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our LUNG earnings forecast.

Pulmonx Co. (NASDAQ:LUNG) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.01. The company earned $14.50 million during the quarter, compared to analysts' expectations of $13.49 million. Pulmonx had a negative trailing twelve-month return on equity of 37.22% and a negative net margin of 102.69%. The company's revenue was up 34.3% on a year-over-year basis. During the same period last year, the company posted ($0.43) earnings per share.

ETFs with the largest weight of Pulmonx (NASDAQ:LUNG) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Health Care Equipment ETF (XHE), BlackRock Future Health ETF (BMED), Principal Healthcare Innovators ETF (BTEC),

Pulmonx updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$65.00 million, compared to the consensus revenue estimate of $64.44 million.

(LUNG) raised $100 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."

Pulmonx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.17%), Braidwell LP (3.08%), FMR LLC (2.55%), State Street Corp (2.51%), Geode Capital Management LLC (1.85%) and Deutsche Bank AG (1.44%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, Richard Ferrari and Scientific Corp Boston.
View institutional ownership trends.

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LUNG stock can currently be purchased for approximately $12.75.

Pulmonx (NASDAQ:LUNG) has a market capitalization of $481.31 million and generates $53.66 million in revenue each year. The company earns $-58,920,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

The company employs 253 workers across the globe.

The official website for the company is pulmonx.com. The company can be reached via phone at 1-650-364-0400 or via email at investors@pulmonx.com.